NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Study to investigate the safety and activity of NEO-PTC-01 in patients with unresectable or metastatic melanoma. NEO-PTC-01 is an autologous personalized T cell (PTC) product for adoptive cell therapy that is manufactured ex vivo and targets neoantigens displayed on the patient's tumor and the tumor microenvironment. The study will be conducted in two parts, Part 1 (Dose Finding) and Part 2 (Dose Expansion). The dose-finding part of the study will test two doses of NEO-PTC-01 and will be structured according to a 3+3 dose escalation design. After the highest tolerated NEO-PTC-01 dose is identified, 2 additional evaluations in Part 1 are planned, a cohort to investigate NEO-PTC-01 in combination with interleukin (IL)-2 and another cohort introducing α programmed cell death protein 1 (αPD-1) therapy. The dose expansion part of the study will test the dose deemed to be safe in the dose-finding part of the study in an expanded cohort of patients to further define the safety of NEO-PTC-01.

NEO-PTC-01 in combination with a fixed dose of IL-2 (cohort will only be open in countries where IL-2 is approved)

The αPD-1 therapy will be introduced, beginning 1 to 2 weeks post NEO-PTC-01, to patients who failed αPD-1/α programmed death ligand 1 (αPD-L1) therapy prior to enrollment in the NTC-001 study

Patients currently receiving PD-1/PD-L1 inhibitors (as single agent or in combination with cytotoxic T-lymphocyte-associated antigen-4 [CTLA4] inhibitors) as therapy for metastatic melanoma

Rate of adverse events (AEs), including serious adverse events (SAEs) and AEs leading to treatment discontinuation

Rate of AEs, including SAEs and AEs leading to treatment discontinuation and those AEs and SAEs detected during symptom-directed physical examinations (changes in safety laboratory evaluations, physical examination findings, and vital signs).

Progression-free survival (PFS), defined as the time from the date of first dosing of NEO-PTC-01 to the date of first documented progressive disease (PD) or death, whichever comes first

Clinical activity endpoints, based on investigator assessment of serial radiographic evaluations [Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)] to determine response to treatment and progression of disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Objective response rate (ORR), defined as the proportion of patients who achieve complete response (CR) or partial response (PR) based on RECIST v1.1

Clinical activity endpoints, based on investigator assessment of serial radiographic evaluations (CT or MRI) to determine response to treatment and progression of disease based on RECIST version 1.1.

Duration of response (DOR), defined as the date of the first documentation of a confirmed response to the date of the first documented PD

Clinical activity endpoints, based on investigator assessment of serial radiographic evaluations (CT or MRI) to determine response to treatment and progression of disease based on RECIST version 1.1.

Clinical benefit rate (CBR), defined as the proportion of patients who achieve CR, PR, or stable disease (SD) based on RECIST v1.1

Clinical activity endpoints, based on investigator assessment of serial radiographic evaluations (CT or MRI) to determine response to treatment and progression of disease based on RECIST version 1.1.

Time to first subsequent therapy, defined as the time from the date of first dosing to the start date of first subsequent therapy

Clinical activity endpoints, based on investigator assessment of serial radiographic evaluations (CT or MRI) to determine response to treatment and progression of disease based on RECIST version 1.1.

Inclusion Criteria: Adult (age 18 to 75) men and women willing and able to give written informed consent. Histologically confirmed unresectable or metastatic melanoma. Part 1: Have previously received a PD-1/PD-L1 inhibitor (either as single agent or in combination) and a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor-containing regimen (single agent or combination) prior to NEO-PTC-01, with disease progression following these therapies or otherwise lack of clinical benefit as determined by the study investigator. Part 2: Have received/are currently receiving a PD-1/PD-L1 inhibitor (as a single agent or in combination with CTLA-4) for at least 3 months. Have documented SD by RECIST v1.1 or clinically asymptomatic progressive disease on the most recent imaging assessment, which must have occurred within 3 months of enrollment. In the opinion of the investigator, are medically eligible and able to continue with PD-1/PD-L1 inhibitor therapy. In the opinion of the investigator, would benefit from the addition of a T-cell based therapy. For known serine-threonine kinase (BRAF) mutant patients: patients must have also received targeted therapy (B-raf inhibitor or B-raf/mitogen-activated protein kinase enzyme [MEK] combination therapy) prior to NEO-PTC-01, unless deemed not appropriate to receive these treatments by the investigator. Have at least one site of measurable disease by RECIST v1.1. At least one site of disease must be accessible to biopsy for tumor tissue for sequence and immunological analysis. The biopsy site may be the same as the measurable site so long as it remains measurable. Surgical resection of the measurable site may not be performed if that site is the only measurable lesion. An archival biopsy may be used in place if the biopsy was taken within 6 months of informed consent. Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicities see below limits for inclusion) or an National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, Grade of 0 or 1, except for toxicities not considered by the treating physician to be a safety risk (e.g., alopecia). Screening laboratory values must meet the following criteria and should be obtained prior to any production phase assessments: White blood cell (WBC) count ≥ 3 × 10^3/μL. Absolute neutrophil count (ANC) ≥ 1.5 × 10^3/μL. Platelet count ≥ 100 × 10^3/μL. Hemoglobin > 9 g/dL or 6 mmol/L. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 50 mL/min by Cockcroft-Gault. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN. Total bilirubin ≤ 1.5 × ULN (except in patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL). International Normalized Ratio (INR), Prothrombin Time (PT), or Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN unless the patient is receiving anticoagulant therapy, as long as PT or aPTT is within therapeutic range of intended use of anticoagulants. Exclusion Criteria: Age greater than 75 years or less than 18 years. Received more than three prior lines of therapy for metastatic disease. Have an active or history of autoimmune disease (known or suspected). Exceptions are permitted for vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition requiring only hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger. Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to enrollment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to enrollment. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical and/or radiographic stability. Active systemic infections requiring intravenous antimicrobial therapy, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, clinically significant cardiac arrhythmias such as uncontrolled atrial fibrillation, ventricular tachycardia, or second- or third-degree heart block, and obstructive or restrictive pulmonary disease. Active major medical illnesses of the immune system including conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to NEO-PTC-01 infusion. Inhaled or topical steroids and adrenal replacement doses (≤ 10 mg daily prednisone equivalents) are permitted in the absence of active autoimmune disease. Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, and/or life-threatening illnesses unrelated to cancer that could, in the investigator's opinion, interfere with participation in this study. Have any underlying medical condition, psychiatric condition, or social situation that, in the investigator's opinion, would interfere with participation in the study. Have a planned major surgery that is expected to interfere with study participation or confound the ability to analyze study data. Are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the end of the trial (EOT) visit. Nursing women are excluded from this study because there is an unknown but potential risk of AEs in nursing infants secondary to treatment of the mother with treatments to be administered in this study. Have a history of another invasive malignancy aside from melanoma, except for the following circumstances: Patient has been disease-free for at least 2 years and is deemed by the investigator to be at low risk for recurrence of that malignancy. Patient was not treated with systemic chemotherapy for carcinoma in situ of the breast, oral cavity, or cervix, basal cell, or squamous cell carcinoma of the skin.